Contineum Therapeutics, Inc. (CTNM)
About Contineum Therapeutics, Inc.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $0
- Net income
- -$60.0M
- Total assets
- $276.6M
- Market cap
- $429.6M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $68.1M
- Operating income
- -$68.1M
- Income tax
- $0
- Net income
- -$60.0M
- EPS (basic)
- $-2.17
- EPS (diluted)
- $-2.17
Balance sheet
- Total assets
- $276.6M
- Current assets
- $267.9M
- Total liabilities
- $15.7M
- Current liabilities
- $9.7M
- Shareholders’ equity
- $261.0M
Cash flow
- Operating cash flow
- -$55.3M
- Investing cash flow
- -$3.7M
- Financing cash flow
- $112.7M
- Net cash flow
- $53.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $429.6M
- EPS (diluted)
- $-2.17
- Shares outstanding
- 30.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 5, 2024
Contineum Therapeutics, Inc. (CTNM) Stock Price
- Reported a net loss of $60.0M in FY2024.
- Trading 14% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Contineum Therapeutics, Inc..
Write a review
News about Contineum Therapeutics, Inc.
News & sentiment via Polygon.io
Contineum Therapeutics, Inc.: frequently asked questions
Is Contineum Therapeutics, Inc. an American company?
Contineum Therapeutics, Inc. is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Contineum Therapeutics, Inc. headquartered?
Contineum Therapeutics, Inc. is headquartered in San Diego, California, United States.
Is Contineum Therapeutics, Inc. publicly traded?
Yes — Contineum Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol CTNM on the NASDAQ.
What does Contineum Therapeutics, Inc. do?
Contineum Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
